Market Research Logo

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Epidemiology Forecast to 2027

DelveInsight's Chronic Kidney Disease (Chronic Renal Failure) - Epidemiology Forecast, 2027 report provides a comprehensive analysis of the Chronic Kidney Disease (Chronic Renal Failure) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2027.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2027

Chronic Kidney Disease (Chronic Renal Failure) Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Chronic Kidney Disease (Chronic Renal Failure) in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Chronic Kidney Disease (Chronic Renal Failure) outlook. It also includes the explanation of changing trends of epidemiology outlining the Chronic Kidney Disease (Chronic Renal Failure) scenario.

Chronic Kidney Disease (Chronic Renal Failure) Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Chronic Kidney Disease (Chronic Renal Failure) thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Chronic Kidney Disease (Chronic Renal Failure) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Chronic Kidney Disease (Chronic Renal Failure) Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Chronic Kidney Disease (Chronic Renal Failure)

Key assessments
• Patient Segmentation in Chronic Kidney Disease (Chronic Renal Failure)
• Chronic Kidney Disease (Chronic Renal Failure) Risk & Burden
• Factors driving growth in a specific Chronic Kidney Disease (Chronic Renal Failure) patient population


1. Report Introduction
2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 2017
2.2. Patient Share Distribution of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 2027
3. Disease Background and Overview: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 7MM
4.3. Total Prevalent/ Incident Patient Population of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 7MM – By Countries
5. Epidemiology of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.1.3. Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) *
5.1.4. Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) *
5.1.5. Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.4.3. Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) *
5.4.4. Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) *
5.4.5. Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.5.3. Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) *
5.5.4. Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) *
5.5.5. Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.6.3. Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) *
5.6.4. Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) *
5.6.5. Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.7.3. Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) *
5.7.4. Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) *
5.7.5. Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.8.3. Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) *
5.8.4. Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) *
5.8.5. Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.9.3. Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) *
5.9.4. Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) *
5.9.5. Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
6. Unmet Needs of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific
List Of Tables
Table 1: Total Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 7MM
Table 2: Total Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in United States (2016-2027)*
Table 5: Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in United States (2016-2027)*
Table 6: Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in United States (2016-2027)
Table 7: Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Germany (2016-2027)
Table 8: Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Germany (2016-2027) *
Table 9: Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Germany (2016-2027) *
Table 10: Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Germany (2016-2027)
Table 11: Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in France (2016-2027)
Table 12: Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in France (2016-2027) *
Table 13: Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in France (2016-2027) *
Table 14: Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in France (2016-2027)
Table 15: Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Italy (2016-2027)
Table 16: Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Italy (2016-2027) *
Table 17: Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Italy (2016-2027) *
Table 18: Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Italy (2016-2027)
Table 19: Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Spain (2016-2027)
Table 20: Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Spain (2016-2027) *
Table 21: Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Spain (2016-2027) *
Table 22: Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Spain (2016-2027)
Table 23: Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in UK (2016-2027)
Table 24: Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in UK (2016-2027) *
Table 25: Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in UK (2016-2027) *
Table 26: Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in UK (2016-2027)
Table 27: Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Japan (2016-2027)
Table 28: Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Japan (2016-2027) *
Table 29: Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Japan (2016-2027) *
Table 30: Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Japan (2016-2027)
List Of Tables
Table 1: Total Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 7MM
Table 2: Total Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in United States (2016-2027)*
Table 5: Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in United States (2016-2027)*
Table 6: Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in United States (2016-2027)
Table 7: Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Germany (2016-2027)
Table 8: Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Germany (2016-2027) *
Table 9: Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Germany (2016-2027) *
Table 10: Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Germany (2016-2027)
Table 11: Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in France (2016-2027)
Table 12: Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in France (2016-2027) *
Table 13: Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in France (2016-2027) *
Table 14: Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in France (2016-2027)
Table 15: Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Italy (2016-2027)
Table 16: Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Italy (2016-2027) *
Table 17: Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Italy (2016-2027) *
Table 18: Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Italy (2016-2027)
Table 19: Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Spain (2016-2027)
Table 20: Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Spain (2016-2027) *
Table 21: Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Spain (2016-2027) *
Table 22: Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Spain (2016-2027)
Table 23: Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in UK (2016-2027)
Table 24: Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in UK (2016-2027) *
Table 25: Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in UK (2016-2027) *
Table 26: Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in UK (2016-2027)
Table 27: Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Japan (2016-2027)
Table 28: Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Japan (2016-2027) *
Table 29: Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Japan (2016-2027) *
Table 30: Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Japan (2016-2027)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report